We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
GeparNuevo HTG (Denkert, C.)
Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy
PD4-02 spotlight poster discussion 4:
Wednesday, December 7, 2022: 7:00 – 8:15. Hemisfair Ballroom 1&2.
PENELOPE-B HER2-Low (Denkert, C.)
Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
HER2-06 poster presentation session at HER2 Low: A Separate Entity Special Session:
Wednesday, December 7, 2022, 9:45 - 11:00. Hall 3.
GeparNuevo Immunomarkers blood (Seliger, B.)
Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients
PD9-04 spotlight poster discussion 9
Wednesday, December 7, 2022: 17:00-18:15. Hemisfair Ballroom 1&2.
AMICA Trial (Decker, T.)
Maintenance therapy with ET and Ribociclib after 1st line chemotherapy (CT) in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (BC): a phase II trial (AMICA)
P3-01-09 poster session 3
Wednesday, December 7, 2022: 17:00-18:15. Hall 1.
CAPItello-291 Trial (Turner, N.)
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
GS3-04 oral presentation
Thursday, December 8, 2022: 9:15-9:30. Hall 3.
Challenging Types of Breast Cancer
Moderator: Bora Lim, MD • Pathologic aspects Jorge S. Reis-Filho, MD, PhD • Metaplastic Alexandra Thomas, MD, FACP • Inflammatory Filipa Lynce, MD • Lobular/pleomorphic Sibylle Loibl, MD, PhD
EDUCATIONAL SESSION BLOCK #3B
Thursday, December 8: 15:00-17:00 (16:30-17:00). Stars at Night Ballroom 1&2.
GeparOLA Trial – Long-Term Survival Data (Fasching, P.A.)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study
GS5-02 oral presentation
Friday, December 9, 2022: 12:15-12:30. Hall 3.
Locoregional Recurrence, Triple Negative Breast Cancer (Krug, D.)
Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy
PD15-06 spotlight poster discussion 15
Thursday, December 8, 2022: 17:00-18:15. Hemisfair Ballroom 1&2.
PENELOPE-B, PALLAS Trials (Loibl, S.)
Development and validation of a composite biomarker predictive of Palbociclib + endocrine treatment benefit in early breast cancer: PENELOPE-B and PALLAS Trials
PD17-05 spotlight poster discussion 17
Friday, December 9, 2022: 7:00-8:15. Stars at Night Ballroom 1&2.
PENELOPE-B Immune Markers (Knudsen, E.S.)
Immunohistochemical markers and determinants of clinical response in the Penelope-B trial
PD17-06 spotlight poster discussion 17
Friday, December 9, 2022: 7:00-8:15. Stars at Night Ballroom 1&2.
